Capadenoson in Angina Pectoris

Bayer

Status and phase: Withdrawn; Phase 2

Conditions: Chronic Stable Angina

Treatments: Drug: Capadenoson (BAY 68-4986); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00518921

EudraCT 2007-000425-22

12484

Details and patient eligibility

About

This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.

Sex: All

Ages: 35 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The primary diagnosis is chronic stable angina of mild-moderate intensity as defined by the Canadian Cardiovascular Society Functional Class II-III, in the presence of definitive coronary artery disease.
• Male or female subjects aged 35 to 75 years (if female, only if postmenopausal or permanently sterilized)
• Stable angina of mild-moderate intensity (Canadian class II-III) with anti-anginal medication not changed for the last 5 weeks

Exclusion criteria

• Inability to withdraw current anti-anginal therapy
• Inability to withdraw any concomitant therapy that would interfere with interpretation of study results

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 4 patient groups, including a placebo group

Arm 1

Experimental group

Treatment:

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Arm 2

Experimental group

Treatment:

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Arm 3

Experimental group

Treatment:

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Drug: Capadenoson (BAY 68-4986)

Arm 4

Placebo Comparator group

Treatment:

Drug: Placebo